Skip to main content
. 2021 Feb 28;13(5):1002. doi: 10.3390/cancers13051002

Figure 4.

Figure 4

Sensitivities to BCL2 and MCL1 inhibition according to lymphoma subtype. We measured cytochrome c release, displayed on the y-axis, after exposure to 1 μM of venetoclax and 10 μM of MS1 in different lymphoma subsets (x-axis). A one-way ANOVA with Tukey multiple comparison was used to determine statistical significance between NHL subtypes. Bars represent the mean ± standard error of mean (SEM). (A) Comparison of lymphoma subtypes based on venetoclax response. CLL, SLL, and HGBL-DH showed notable responses to BCL2 inhibition. (B) Venetoclax responses in DLBCL and HGBL-DH samples according to BCL2 protein expression (present in >50% of cells). Venetoclax responses were not seen in high-grade NHL in the absence of BCL2. T-test with Welch’s correction was applied to assess significance. (C) MS1 responses in lymphoma subtypes. SLL displays the greatest response to single MCL1 inhibition. (D) NHL response to dual inhibition of BCL2 and MCL1 by venetoclax and MS1. All subtypes display increased responses when compared to singular inhibition. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; DLBCL, diffuse large B cell lymphoma; HGBL-DH, high grade B cell lymphoma with translocations in MYC and BCL2; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma.